Pseudomonas vaccine - Aventis Behring
Latest Information Update: 09 Oct 1998
Price :
$50 *
At a glance
- Originator Aventis Behring LLC
- Class Bacterial vaccines; Pseudomonas vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 09 Oct 1998 No-Development-Reported for Pseudomonal infections in Germany (IM)
- 19 Nov 1996 Phase-I clinical trials for Pseudomonal infections in Germany (IM)